Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 5, 2026, by Xilio Therapeutics, Inc., a Delaware corporation and emerging growth company. The report discloses the exercise of Series B warrants issued in connection with a June 2025 follow-on public offering and provides an update on outstanding share counts and financial guidance.
Key Financial Metrics and Capital Structure
- Warrant Exercise Proceeds: The Company received $35.8 million in total gross proceeds from the exercise of 48,207,815 Series B warrants.
- Share Issuance: The exercise resulted in the issuance of 8,202,815 shares of common stock and 40,005,000 prefunded warrants in lieu of shares.
- Outstanding Shares: As of January 2, 2026, there were 67,540,930 shares of common stock issued and outstanding.
- Outstanding Warrants: 48,207,815 Series C warrants remain outstanding, exercisable between June 1, 2026, and December 2, 2026, at an exercise price of $0.75 per warrant.
- Potential Future Proceeds: Full exercise of outstanding Series C warrants could generate up to $36.2 million in additional gross proceeds.
Material Changes
The primary material change reported is the significant capital raise via the exercise of Series B warrants, which increased the company's cash position by $35.8 million and expanded the share count. Additionally, 18,468,185 Series C warrants expired due to the expiration of unexercised Series B warrants.
Guidance, Outlook, and Risks
Liquidity Outlook: Management anticipates that existing cash and cash equivalents, combined with the net proceeds from the Series B warrant exercises, will be sufficient to fund operating expenses and capital expenditure requirements into the second quarter of 2027.
Risks and Contingencies: The filing includes forward-looking statements regarding the potential exercise of Series C warrants and the sufficiency of cash. These statements are subject to risks including general market conditions and other uncertainties detailed in the Company's most recent Form 10-Q for the period ended September 30, 2025. The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the exact net proceeds from the Series B warrant exercise after deducting underwriting discounts and offering expenses.
- Review the most recent Form 10-Q (ended September 30, 2025) for detailed cash burn rates and operating expense trends.
- Monitor the exercise activity of the 48,207,815 outstanding Series C warrants during their June 2026 to December 2026 window.
- Confirm the dilution impact of the 40,005,000 prefunded warrants issued in lieu of common stock.